US Biopharma & Biotech: Bernstein recaps private-biotech pipeline differentiation, with 2027–28 clinical readouts set to test the major claims

Overview

Bernstein summarizes selected sessions from its second Best of Biotech Symposium, centered on private companies pursuing differentiated approaches in metabolic, respiratory, inflammatory and cardiometabolic disease. The report frames clinical validation, safety, PK and financing/partnering milestones as the main determinants of whether these early-stage theses hold.

Core views

Confo Therapeutics is developing a GPCR-focused platform built on llama-derived VHHs that lock receptors into specific conformations, enabling screening for desired pharmacology. Its wholly owned SSTR5 agonist antibody, CFTX-2034, is intended initially for post-bariatric hypoglycemia and is expected to enter the clinic in early 2027. Management argues that suppressing insulin, GLP-1 and GIP secretion could address the disease through three pathways; the principal stated risk is hyperglycemia at high doses, making controlled PK/PD and stable exposure central to the program. Separately, Lilly has moved partnered AT2R antagonist CFTX-1554 into Phase 2a in diabetic neuropathy, osteoarthritis and chronic low-back pain. The deal carries approximately $590 million of milestones per product for up to two products, tiered royalties and a co-investment option, though visibility on partnered-program disclosure remains limited. Bernstein identifies CFTX-2034 data, material financing and/or an obesity partnership as key Confo validation events. Kinaset’s thesis is that inhaled pan-JAK inhibitor frevecitinib could provide broad asthma activity across T2-high and T2-low disease while offering an inhaler-based alternative to injectable biologics. Management cited research suggesting roughly a 4:1 patient and prescriber preference for inhalers over injectables, and argues that the drug’s single-inhalation dry-powder formulation differentiates it from prior inhaled JAK programs that required multiple capsules or puffs. The company reports around 50% delivery efficiency versus a typical 25%, which it believes creates room for future fixed-dose combinations. Early evidence included FeNO declines and FEV1 improvements of approximately 120–150 mL after 10 days in moderate-to-severe asthma, including T2-low patients. The decisive test is a 12-week, 512-patient Phase 2b comparing 2 mg once daily, 4 mg once daily and 4 mg twice daily against placebo; it targets a 150 mL FEV1 improvement in T2-high patients and 120 mL in all comers. A futility and safety interim analysis is expected in 2H27 and topline data in Q1 2028. Potential label and longer-duration safety uncertainty remain important because human exposure so far is limited to 10 days. Ambrosia Biosciences is pursuing AMB-702, a once-daily oral GLP-1 agonist, on formulation and PK rather than a new mechanism. Management’s differentiation claims are single-digit-milligram human dosing, a flat 24-hour exposure profile intended to avoid daily Cmax-related tolerability issues, and easier combination with other oral agents. Preclinical results cited included approximately 50% better weight loss than injected semaglutide in a lean non-human-primate model and 12.6% placebo-adjusted weight loss at seven days versus 5.4% for orforglipron at the same dose and formulation in a reported head-to-head study. Bernstein emphasizes that these claims remain preclinical. First human dosing is targeted for Q1 2027; the critical Phase 1 output will be human PK and tolerated dose range rather than large efficacy data, and management views that readout as a likely business-development trigger. A $100 million Series B closed in March 2026 and is intended to fund the company through the Phase 1 readout. Belenos is advancing long-acting TSLP/IL-13 bispecific BEL512 across CRSwNP, asthma and other inflammatory diseases. Its premise is that dual blockade can address heterogeneous tissue biology better than single-target biologics, while extended dosing could matter in a post-2031 market expected by management to include generic dupilumab. In Keymed’s 120-patient China CRSwNP Phase 2, every endpoint was statistically significant by week 24 and management said benefits appeared by week four and persisted to nine months in single-dose arms; 300 mg every 24 weeks was selected for Phase 3. In a 50-patient US asthma Phase 1b interim analysis, management reported a 48% FeNO reduction by day four, 26% lower eosinophils versus placebo and a 181 mL placebo-adjusted FEV1 gain in moderate patients; by week eight, FeNO had fallen 65%, eosinophils were 50% below placebo by week five, and FEV1 was 330 mL placebo-adjusted by week seven in moderates. Global CRSwNP Phase 3 is planned for 1H27 and asthma Phase 3 for 2H27. The central unresolved issue is whether dual-pathway blockade can outperform established biologics in controlled global studies. Corteria has three first-in-class programs centered on CRF2 agonism across obesity, pulmonary hypertension and heart failure. Its largest near-term catalyst is the year-end Phase 1 obesity readout for once-weekly COR-1389. Management’s success threshold is meaningful weight loss driven by fat reduction with preserved muscle and no meaningful gastrointestinal burden; whole-body MRI is used rather than DEXA to assess fat distribution and muscle-related fat. Management reported that patients reaching target exposure showed prominent 12-week weight response, fat loss with muscle preservation, good GI tolerability and no titration, but the report notes that the claimed best-in-class positioning rests on management’s cross-reading of public data rather than head-to-head evidence. For COR-1167 in worsening heart failure, the 300-patient CRAFT-WHF trial was suspended after the DSMB concluded that eligibility criteria allowed excessively ill patients to enroll. The revised exclusions remove impending cardiogenic shock with elevated screening lactate and severe chronic liver disease while retaining congestion criteria; regulatory feedback is expected in October, enrollment restart in November and last-patient-in in Q2 2027. Corteria reports runway through end-2028, with the obesity readout identified as the biggest swing factor over the next 12 months. On the market backdrop, Bernstein’s macro and healthcare specialists noted that biotech ETF primary-market flows have improved since September 2025, with a stronger recovery relative to assets under management for the iShares Biotechnology ETF after prior outflows. They characterized healthcare as working as an anti-AI trade and noted limited biotech factor correlation aside from some relationship with inflation. The discussion also highlighted liquidity cycles: biotech had outperformed the S&P 500 by 40% over the preceding 12 months, but the specialists argued that contemporary liquidity cycles are smaller than those during QE-infinity, implying smaller biotech cycles as well.

Analysis framework

The report recaps management presentations and fireside discussions, then evaluates each company through mechanism, claimed differentiation, preclinical or clinical evidence, development design, safety considerations, financing and anticipated catalysts. It also places the private-company discussion in the context of biotech ETF flows, factor correlations and liquidity conditions.

Methodology notes

• Industry AnalysisSupply-demand framework

  Biotech liquidity and ETF-flow analysis

  The macro discussion uses ETF primary-market flows and assets under management to assess whether investor liquidity conditions are becoming more supportive for biotech.

• Competition & strategyEconomic Moat and Competitive Advantage

  Platform, formulation and delivery differentiation

  The company discussions test whether differentiated receptor platforms, oral PK, long-acting dosing, or inhaled delivery could create an advantage over existing or competing therapies.

• Event-Driven and Behavioral FinanceEvent-driven analysis

  Clinical and financing catalysts

  The report identifies specific data readouts, trial milestones, financing events and partnering opportunities that could validate or challenge each private-company thesis.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Confo Therapeutics

  Private GPCR-platform developer with near-term clinical and partnered-program validation events.

  Strengths

  ConfoBody platform; CFTX-2034 targets PBH through SSTR5; Lilly’s Phase 2a CFTX-1554 program provides external validation.

  Weaknesses

  Limited visibility into partnered-program disclosure and early clinical stage of the wholly owned lead asset.

  Comparison

  Management argues orthosteric agonist antibodies differentiate Confo from other GPCR specialists and may be difficult for AI-based de novo design.

  Risks

  CFTX-2034 may cause hyperglycemia at high doses; clinical PK/PD control remains to be established.

• Kinaset Therapeutics

  Private developer of inhaled pan-JAK inhibitor frevecitinib for asthma and potentially COPD.

  Strengths

  Single-inhalation dry-powder formulation, claimed broad T2-high/T2-low activity and early FEV1/FeNO signals.

  Weaknesses

  Human exposure is limited to 10 days and the pivotal differentiation thesis awaits Phase 2b data.

  Comparison

  Management contrasts its single inhalation with multi-capsule or multi-puff delivery used by prior inhaled JAK programs.

  Risks

  Potential JAK-class warning, longer-term safety uncertainty and Phase 2b efficacy risk, especially in T2-low disease.

• Ambrosia Biosciences

  Private oral-obesity-drug developer centered on once-daily GLP-1 AMB-702.

  Strengths

  Proposed single-digit-milligram dosing, flat 24-hour PK and potential oral combination flexibility.

  Weaknesses

  Core differentiation claims are based on animal and preclinical data rather than human PK or efficacy.

  Comparison

  Management positions AMB-702 against first-generation oral GLP-1 therapies and argues its dosing and PK could be superior.

  Risks

  Phase 1 must demonstrate the proposed PK and tolerability profile; combination programs remain preclinical.

• Belenos Biosciences

  Private inflammatory-disease developer of TSLP/IL-13 bispecific BEL512.

  Strengths

  Positive management-reported CRSwNP and asthma data, long-acting dosing potential and dual-pathway rationale.

  Weaknesses

  Cross-trial comparisons with established biologics are not controlled comparisons.

  Comparison

  Management argues BEL512 could deliver faster and deeper effects than established single-target biologics.

  Risks

  Global Phase 3 must confirm efficacy, safety and differentiation versus established biologics.

• Corteria Pharmaceuticals

  Private cardiometabolic developer advancing CRF2 agonists in obesity, pulmonary hypertension and heart failure.

  Strengths

  Multiple programs, runway through end-2028 and a thesis around fat loss with muscle preservation.

  Weaknesses

  COR-1389 best-in-class claims lack head-to-head evidence; COR-1167 required a trial pause and eligibility revision.

  Comparison

  Management benchmarks COR-1389 against Hanmi’s HM17321 and public peptide data, but did not provide molecular specifics.

  Risks

  The obesity readout is the principal value swing factor; revised heart-failure trial execution and regulatory feedback are critical.

Key data

• Confo CFTX-1554 deal milestonesApproximately $590 million per product for up to two productsAlso includes tiered royalties and a Phase 2b/3 co-investment option.
• Kinaset Phase 2b enrollment512 patients12-week placebo-controlled asthma study; interim analysis expected in 2H27 and topline data in Q1 2028.
• Kinaset Phase 2b FEV1 targets150 mL in T2-high patients; 120 mL in all comersTargets for frevecitinib efficacy.
• Ambrosia Series B$100 millionClosed in March 2026 and intended to fund through AMB-702 Phase 1 readout.
• Belenos asthma interim FEV1181 mL by day four; 330 mL by week sevenPlacebo-adjusted gain in moderate patients, as reported by management.
• Corteria COR-1167 trial300 patients across three doses at 55 sitesCRAFT-WHF was paused to revise eligibility criteria; last-patient-in is targeted for Q2 2027.
• Biotech relative performance40% outperformance versus the S&P 500 over the last 12 monthsCited in the macro discussion.

Impact & implications

The report portrays the private-biotech opportunity set as rich in differentiated scientific approaches but dependent on a concentrated set of forthcoming clinical and PK validation events. Improved biotech flows and relative performance may support the sector backdrop, while the company-specific outcomes remain driven by trial execution, safety, durability of effect and financing or partnering progress.

Risks

• Confo’s CFTX-2034 could cause hyperglycemia at high doses, making stable exposure and PK/PD control essential.
• Kinaset has limited human exposure data and must establish safety and efficacy, particularly in T2-low asthma.
• Ambrosia’s claimed oral GLP-1 advantages remain preclinical until Phase 1 human PK and tolerability data are available.
• Belenos must show that dual TSLP/IL-13 blockade delivers differentiated results in controlled global studies.
• Corteria’s obesity and heart-failure programs face clinical-readout and trial-execution risk following the CRAFT-WHF pause.

What to watch

• Confo’s CFTX-2034 IND timing, early-2027 first dosing, Lilly’s CFTX-1554 Phase 2a signals, and potential financing or obesity partnership.
• Kinaset’s 2H27 interim analysis and Q1 2028 topline Phase 2b results for frevecitinib.
• Ambrosia’s Q1 2027 first-in-human AMB-702 study, particularly its human PK profile and tolerated dose range.
• Belenos’s CRSwNP Phase 3 start in 1H27, asthma Phase 3 in 2H27, and further asthma Phase 1b data.
• Corteria’s year-end COR-1389 obesity readout, October regulatory feedback and November CRAFT-WHF enrollment restart.